Nektar Therapeutics Inc (NKTR)

20.79
NASDAQ : Health Care
Prev Close 21.50
Day Low/High 20.75 / 21.49
52 Wk Low/High 11.41 / 24.88
Avg Volume 2.22M
Exchange NASDAQ
Shares Outstanding 155.15M
Market Cap 3.34B
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Warren Buffett's Wisdom: Cramer's 'Mad Money' Recap (Monday 5/8/17)

Warren Buffett's Wisdom: Cramer's 'Mad Money' Recap (Monday 5/8/17)

The Oracle of Omaha believes in the future of U.S. business, says Jim Cramer. Plus, Buffett can admit his mistakes and we can learn from that.

First Week of June 16th Options Trading For Nektar Therapeutics (NKTR)

Investors in Nektar Therapeutics saw new options become available this week, for the June 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new June 16th contracts and identified one put and one call contract of particular interest.

Nektar Therapeutics Presents New Preclinical Data For Its Immuno-Oncology Programs At The American Association For Cancer Research (AACR) Annual Meeting

Five Data Presentations Showcased Nektar's Immuno-Oncology Candidates, NKTR-214 and NKTR-255

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Verizon, Randgold Resources, Bank of America: 'Mad Money' Lightning Round

Jim Cramer is bullish on Nektar Therapeutics and Alkermes, as well as Verizon and Bank of America.

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Profit-Taking Is Only Natural: Cramer's 'Mad Money' Recap (Monday 4/3/17)

Jim Cramer says what's more noteworthy than the pullback is the day's strong rebound.

Nektar Therapeutics Initiates Clinical Study Of NKTR-358, A First-in-Class Regulatory T Cell Stimulator, Being Developed For The Treatment Of Immune And Inflammatory Disorders

NKTR-358 is designed to correct the underlying immune system dysfunction common to many auto-immune diseases

Traders Are Aggressively Fading the Open

Traders Are Aggressively Fading the Open

But what will be most important is whether support stays strong and the buyers show interest in the afternoon.

Rev's Forum: Don't Just Sit There, Do Something!

Rev's Forum: Don't Just Sit There, Do Something!

Why not buy something and try to make some money rather than waste time predicting how this will all come to an ugly end?

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

How to Trade Monday's Most Active Stocks - AMD, Esperion Therapeutics, Nokia and More

Here's how to trade six of the most active names on the market this afternoon.

Biotechs Remain the Best Place For Stock Picking

Biotechs Remain the Best Place For Stock Picking

Biotech companies show more energy than the rest of the market Monday.

Biotech Premarket Movers: CytomX, Aevi, Esperion

Biotech Premarket Movers: CytomX, Aevi, Esperion

CytomX Therapeutics, Aevi Genomic Medicine and Esperion Therapeutics were among the biotech stock movers in premarket trading on Monday.

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar Addiction-Resistant Opioid Reduces Chronic Pain in Late-Stage Study

Nektar plans to out-license the experimental opioid NKTR-181 to a partner for continued development.

NKTR-181 Meets Primary And Secondary Endpoints In Phase 3 SUMMIT-07 Study In Chronic Pain

NKTR-181 Significantly Reduced Pain in Patients with Moderate to Severe Chronic Low Back Pain

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

Finding the stocks that have changed direction.

Nektar Therapeutics Announces Upcoming Presentations At The American Association For Cancer Research Annual Meeting

Five Data Presentations Will Showcase Nektar's Immuno-oncology Candidates, NKTR-214 and NKTR-255

Interesting NKTR Put And Call Options For March 17th

Interesting NKTR Put And Call Options For March 17th

Investors in Nektar Therapeutics saw new options begin trading this week, for the March 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the NKTR options chain for the new March 17th contracts and identified one put and one call contract of particular interest.

First Week of NKTR August 2017 Options Trading

First Week of NKTR August 2017 Options Trading

Investors in Nektar Therapeutics saw new options begin trading this week, for the August 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.